Supplementary Materials: Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotection of Olmesartan in Metabolic Syndrome Patients

Tomoko Mizushige, Hiroyuki Kobori, Hirofumi Hitomi, Yoko Nishijima, Fumihiro Tomoda, Satoshi Morimoto, Masakazu Kohno and Akira Nishiyama

**Figure S1.** Trial profile: 33 patients were recruited; nine patients were excluded (six participants were excluded because of the withdrawal from this study, and three participants were excluded because of the incomplete samplings), and consequently, 24 patients were analyzed.